Tirzepatide for the Treatment of NASH

Time: 11:30 am
day: Day 1 Stream 3 AM


• Hearing how Tirzepatide shows improvement in NASH biomarkers and relevant metabolic traits in phase 2 and phase 3 trials in patients with T2D
• Revealing how Tirzepatide shows profound lowering in liver fat – a phase 3 MRI addendum in T2D
• Discovering SYNERGY-NASH: Tirzepatide Phase 2 design